Abstract

BackgroundAge-related macular degeneration (AMD) is a leading cause of visual impairment in the elderly. The neovascular (wet) form of AMD can be treated with intravitreal injections of different anti-vascular endothelial growth factor (VEGF) agents. Placental growth factor (PGF) is another member of the VEGF family of cytokines with pro-angiogenic and pro-inflammatory effects. Here, we aimed to compare single and combined inhibition of VEGF-A and PGF in the laser-induced mouse model of choroidal neovascularization (CNV) with a focus on the effects on retinal mononuclear phagocytes.MethodsCNV was induced in C57BL/6J mice using a YAG-Laser. Immediately after laser damage antibodies against VEGF-A (aVEGF), anti-PGF (aPGF), aVEGF combined with aPGF, aflibercept, or IgG control were injected intravitreally in both eyes. Three and 7 days after laser damage, the vascular leakage was determined by fluorescence angiography. Lectin staining of retinal and RPE/choroidal flat mounts was used to monitor CNV. In situ mRNA co-expression of Iba1, VEGF and PGF were quantified using in situ hybridization. Retinal and RPE/choroidal protein levels of VEGF and PGF as well as the pro-inflammatory cytokines IL-6, IL1-beta, and TNF were determined by ELISA.ResultsEarly (day 3) and intermediate (day 7) vascular leakage and CNV were significantly inhibited by PGF and VEGF-A co-inhibition, most effectively with the trap molecule aflibercept. While VEGF-A blockage alone had no effects, trapping PGF especially with aflibercept prevented the accumulation of reactive microglia and macrophages in laser lesions. The lesion-related mRNA expression and secretion of VEGF-A and PGF by mononuclear phagocytes were potently suppressed by PGF and partially by VEGF-A inhibition. Protein levels of IL-6 and IL1-beta were strongly reduced in all treatment groups.ConclusionsRetinal inhibition of PGF in combination with VEGF-A prevents vascular leakage and CNV possibly via modulating their own expression in mononuclear phagocytes. PGF-related, optimized strategies to target inflammation-mediated angiogenesis may help to increase efficacy and reduce non-responders in the treatment of wet AMD patients.

Highlights

  • Age-related macular degeneration (AMD) is a leading cause of visual impairment in the elderly

  • Aflibercept strongly inhibits vascular leakage and choroidal neovascularization We first compared the effects of inhibiting vascular endothelial growth factor (VEGF)-A alone, Placental growth factor (PGF) alone, or in combinations with Immunoglobulin G (IgG) sham injections in the laser-induced mouse model of CNV

  • At 3 days after laser induction, anti-PGF alone, the combination of aVEGF with aPGF, and aflibercept significantly reduced the pixel intensity of vascular leakage compared to IgG

Read more

Summary

Introduction

Age-related macular degeneration (AMD) is a leading cause of visual impairment in the elderly. Placental growth factor (PGF) is another member of the VEGF family of cytokines with pro-angiogenic and pro-inflammatory effects. Age-related macular degeneration (AMD) is a frequent cause of visual impairment in the Western world, leading to considerable limitations in the daily life of elderly people [1]. Progressive degeneration of photoreceptors occurs and a strong immunological response is mounted in the retina and RPE/choroid. This latent para-inflammation is characterized by local microgliosis, infiltration of inflammatory macrophages in the subretinal space, and dysregulation of the complement system [4]. Modulation of the pro-inflammatory state of microglia and macrophages may be a therapeutic strategy for retinal degenerative diseases [7]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call